An Update on SARS-CoV-2
Friday, October 16, 2020
The first IABS webinar (May 27th) provided insight into what was known at that point in time about SARS-CoV-2:
the epidemiology worldwide; the disease from an immunology viewpoint and the development of vaccines against the virus.
This 3rd International Alliance for Biological Standardization COVID-19 webinar brought together a broad range of
international stakeholders, including academia, regulators, funders and industry, with a considerable delegation
from low- and middle-income countries, to provide an update on
the virology, epidemiology and immunology of, and the vaccine development for SARS-CoV-2,
six months after the previous webinar.
Although SARS-CoV-2 shows limited evolution, which is beneficial for vaccine development,
recombination of SARS-CoV-2 with another CoV has led to enhanced human-to-human transmissibility of the virus.
Read the Meeting Report
For further information : - CR20 - Seqirus - Wellcome Trust - Boehringer Ingelheim - hVIVO - HIC-Vac
- Prof. Bruno Lina, professor of Virology, University Claude Bernard Lyon and Director of the research laboratory VirPat - Slides - Replay
- Prof. Arnaud Fontanet, Director of the Department of Global Health, Head of the Emerging Diseases Epidemiology Unit, Institut Pasteur - Slides - Replay
- Prof. Arnaud Marchant, Director of the Institute for Medical Immunology, Université Libre de Bruxelles - Slides - Replay
- Dr. Melanie Saville, Head of Vaccine R&D, CEPI Vaccines - Slides - Replay
The complete set of speakers slides are available Here
14:00 Welcome & Introduction
Dr. Joris Vandeputte, President, IABS
14:05 Epidemiology: the latest data on the pandemic
Prof. Arnaud Fontanet
14:20 What do we now know about the SARS-CoV-2 virus?
Prof. Bruno Lina
14:35 The disease from the viewpoint of an immunologist
Prof. Arnaud Marchant
14:50 Vaccine development - where are we now?
Dr. Melanie Saville
Dr. Joris Vandeputte
16:00 End of webinar
IABS offers Open Access to its SARS-CoV-2 series of webinars